Progyny (NASDAQ:PGNY) Rating Increased to Strong-Buy at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Progyny (NASDAQ:PGNY – Free Report) from a buy rating to a strong-buy rating in a report issued on Saturday morning,Wall Street Zen reports.

Other analysts have also issued reports about the stock. Jefferies Financial Group set a $33.00 price target on shares of Progyny in a research report on Tuesday, September 8th. Weiss Ratings downgraded shares of Progyny from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Citizens Jmp boosted their price objective on shares of Progyny from $31.00 to $33.00 and gave the stock a “market outperform” rating in a research note on Tuesday, September 8th. Bank of America upped their target price on shares of Progyny from $29.00 to $31.00 and gave the company a “buy” rating in a report on Tuesday, June 2nd. Finally, KeyCorp raised their target price on shares of Progyny from $30.00 to $35.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Progyny presently has an average rating of “Moderate Buy” and an average target price of $34.36.

Read Our Latest Stock Analysis on PGNY

Progyny Stock Up 0.4%

PGNY stock opened at $27.13 on Friday. The business has a 50 day moving average price of $28.37 and a two-hundred day moving average price of $24.25. The company has a market cap of $2.08 billion, a price-to-earnings ratio of 29.49, a P/E/G ratio of 1.87 and a beta of 0.99. Progyny has a twelve month low of $16.10 and a twelve month high of $33.06.

Progyny (NASDAQ:PGNY – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. The company had revenue of $350.51 million for the quarter, compared to analysts’ expectations of $349.05 million. Progyny had a return on equity of 15.98% and a net margin of 6.00%.The business’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.19 EPS. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. On average, equities research analysts anticipate that Progyny will post 1.25 EPS for the current fiscal year.

Progyny announced that its Board of Directors has approved a stock repurchase program on Tuesday, May 26th that authorizes the company to buyback $200.00 million in shares. This buyback authorization authorizes the company to reacquire up to 10.3% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board believes its stock is undervalued.

Insider Buying and Selling

In related news, Director Kevin Gordon sold 11,500 shares of the company’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $27.94, for a total value of $321,310.00. Following the transaction, the director owned 6,792 shares in the company, valued at approximately $189,768.48. This represents a 62.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 9.90% of the company’s stock.

Institutional Investors Weigh In On Progyny

Several hedge funds have recently bought and sold shares of PGNY. Public Employees Retirement System of Ohio acquired a new position in shares of Progyny in the second quarter valued at approximately $29,000. Nykredit A S bought a new position in shares of Progyny during the second quarter worth approximately $38,000. Hantz Financial Services Inc. lifted its holdings in Progyny by 79.4% during the 4th quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock worth $43,000 after purchasing an additional 742 shares during the last quarter. IFP Advisors Inc lifted its holdings in Progyny by 376.0% during the 2nd quarter. IFP Advisors Inc now owns 1,961 shares of the company’s stock worth $57,000 after purchasing an additional 1,549 shares during the last quarter. Finally, Toth Financial Advisory Corp acquired a new stake in Progyny during the 2nd quarter worth approximately $65,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Company Profile

(Get Free Report)

Progyny, Inc is a benefits management company that provides fertility and family-building solutions to employers and their employees. Its platform is designed to support individuals and couples pursuing fertility treatment, including in vitro fertilization, egg freezing, donor services, gestational surrogacy and adoption.

The company’s services combine access to a network of fertility specialists with personalized guidance, care coordination and treatment support. Progyny also offers pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.

Progyny primarily serves employer-sponsored benefit programs in the United States.

Read More